Introduction {#Sec1}
============

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) in which the cytokines and the inflammatory process are key factors. Cytokines like interleukin (IL)-4, IL-2, or interferon gamma (IFN-γ) have been widely studied in MS because of their immunomodulatory role. A critical step in the inflammatory process underlying MS pathology is immune cell trafficking across the blood--brain barrier, and this is associated with worsening clinical symptoms. Natalizumab (Tysabri^®^, Biogen Idec, CA), a monoclonal antibody designed against the α4 subunit of α4β1 (very late antigen-4; VLA-4) and α4β7 receptors located on the lymphocyte surface, has demonstrated efficacy in reducing disease activity and relapse frequency in MS patients and is widely accepted as a drug for the relapsing--remitting subtype of multiple sclerosis (RRMS)\[[@CR1]--[@CR3]\]. The humanized IgG4 specifically binds to the surface of mononuclear circulating blood cells presenting α4, thus inhibiting the adhesion to the VCAM at the endothelium and decreasing extravasation to adjacent tissues. In the context of MS, which is usually considered a T cell autoimmune disease affecting the CNS, the beneficial effects observed with the treatment have been attributed to immunosuppression by a blockade on T cell trafficking through the endothelium \[[@CR4], [@CR5]\].

The clinical improvement and efficacy observed in natalizumab treatment are counter-weighted by important side effects including opportunistic infections and also cases of fatal progressive multifocal leukoencephalopathy (PML) detected during the clinical trials \[[@CR1]\]. Some questions still remain unresolved as the effect of natalizumab in the first days and months of treatment when allergic reactions and acute infusion reactions can occur \[[@CR6]\]. Antibody binding to the VLA-4 receptor may not only play a role in inhibiting the inflammation process but also have effects on the immune system itself.

Although the mechanism of action of the drug is supposed to be clear, the biological effects of integrin α4 blockade or T cell traffic inhibition are still unknown. Already existing drugs for MS like interferon-beta or glatiramer acetate seem to modify CD4^+^ CD25^+^ Foxp3 regulatory T cell activity \[[@CR7]--[@CR10]\] or promote the anti-inflammatory cytokine pathway \[[@CR11]--[@CR14]\]. The goal of our study was to gain insight into the immunological effects of natalizumab treatment in RRMS patients over a period of 20 months with a focus on pro-inflammatory and anti-inflammatory cytokine protein levels as well as regulatory T cell frequency and suppressor function.

Patients and Methods {#Sec2}
====================

Patients {#Sec3}
--------

Twenty-two RRMS patients were recruited and followed in an observational longitudinal cohort study over a period of 20 months after starting treatment with natalizumab (standard---300 mg IV every 4 weeks). All patients fulfilled the McDonald criteria for relapsing--remitting multiple sclerosis \[[@CR15]\]. Clinical follow-up consisted of neurological visits with a rating on the expanded disability status scale (EDSS) every 6 months. Blood samples were taken at 2 h; 4, 7, and 15 days; and 1 and 2 months, and one sample from the 3--5-, 9--12-, and 15--20-month periods, always before drug infusion; all samples were processed within 2 h of extraction. All patients had been treated with immunomodulatory treatments (glatiramer acetate or β-interferon) before starting with natalizumab (minimum wash-out period of 1 month except 15 days for one patient). Patients treated with immunosuppressive drugs or with corticosteroids for relapses less than 30 days before starting with natalizumab were not included in this study. Control blood samples were obtained from healthy donors recruited in our facilities (six women and five men; age range, 25--30 years old). The study was approved by the ethics committee of our hospital, and all patients and controls included signed an informed consent.

The mean age of RRMS patients was 35.53 ± 8 years, and women comprised the 75% (Table [I](#Tab1){ref-type="table"}). The median EDSS at the beginning of the study was 3.69 and 3.73 after 1 year. The annual relapse rate (ARR) was 2.5, and the disease duration was 9.95 ± 6 years. None of the patients received immunomodulatory or immunosuppressive drug treatment during the experiment, and one patient interrupted treatment due to allergic side effects within the first 2 months. Clinical laboratory parameters showed increased levels in the total lymphocytes after 1 year. We obtained significantly higher levels of IL-2, IL-8, and IFN-γ when comparing RRMS patients at baseline with healthy controls (Table [II](#Tab2){ref-type="table"}), which agrees with previous MS reports. Table IPatients' characteristics at baseline and after treatmentClinical laboratory dataRRMS (*n* = 22)Mean age (years)35.53 ± 8Sex (men/women)5/17Men disease duration (years)9.95 ± 6EDSS (number of subjects)0--3.584--6.514Mean EDSS (initial/after 1 year)3.69/3.73Treatments in the last 60 daysGlatiramer acetate8Interferon-β14Corticosteroids/others0Naïve patients0Mean number of relapsesPrevious year1.73First year with natalizumab0.29% of relapse reduction83.1%Median cell count \[baseline/1st Year/2nd year\]Total lymphocytes (×10^3^/μL)1.91/2.64/3.43Total monocytes (×10^3^/μL)0.51/0.49/0.52CD4 (%)39.0%/41.0%/41.0%CD8 (%)33.0%/26.0%/25.0%Table IILevels of cytokines in RRMS patients (baseline) compared to controlsCytokinesRRMSControlsCytokinesRRMSControlsIL-1α4.53 (±2.23)5.03 (±3.67)IL-12p704.11 (±1.25)3.25 (±1.68)IL-1β2.44 (±0.5)1.98 (±1.22)IL-132.75 (±1.05)2.5 (±1.21)IL-215.53 (±4.83)\*12.30 (±1.23)\*IL-174.41 (±1.76)4.22 (±1.35)IL-43.50 (±1.28)3.06 (±2.02)IFN-γ4.58 (±2.3)\*2.51 (±1)\*IL-51.99 (±0.6)2.2 (±0.9)TNF-α6.55 (±2.56)5.80 (±1.53)IL-64.01 (±2.25)5.86 (±3.02)GM-CSF2.72 (±1.25)4.5 (±3.10)IL-826.31 (±11.56)\*11.54 (±4.12)\*MCP-198.28 (±49.25)74.25 (±39.25)IL-103.26 (±1.4)3.36 (±1.30)All concentrations are given in picograms per milliliter. Means and SD are shown\**p* \< 0.05

Clinical disease activity was evaluated with the EDSS scale. Patients were classified in subgroups according to EDSS values (0--3.5, 4--6.5) and the evidence of relapses within the first year (yes or none). Laboratory parameters were measured including LDH, transaminases, total lymphocytes, eosinophils and monocytes, and the total CD4 and CD8 counts.

### Cytokine Determination {#Sec4}

All serum samples for cytokine determination were obtained from 8 mL of fresh blood, centrifuged and stored in 1.5 mL tubes, and frozen at −80°C until measured by flow cytometry (CBA FlexSet---BD^®^Bioscience, Bedford, MA, USA) following manufacturer's instructions. Experiments were carried out using a FACSCalibur Flow Cytometer (BD Bioscience, USA). Cytokines analyzed included in our analysis panel were (lower detection limits are shown): IL-1α (1.0 pg/mL), IL-1β (2.3 pg/mL), IL-2 (11.2 pg/mL), IL-4 (1.4 pg/mL), IL-5 (1.1 pg/mL), IL-6 (1.6 pg/mL), IL-8 (1.2 pg/mL), IL-10 (0.13 pg/mL), IL-12p70 (0.6 pg/mL), IL-13 (0.6 pg/mL), IL-17A (0.3 pg/mL), MCP-1 (1.3 pg/mL), GM-CSF (0.2 pg/mL), tumor necrosis factor (TNF; 0.7 pg/mL), and INF-γ (1.8 pg/mL). All concentrations were transformed according to NIBSC/WHO standards.

### Regulatory T Cell Frequency and Activity {#Sec5}

PBMCs were isolated from 18 mL of fresh blood samples (stored in EDTA tubes) through Ficoll-Paque (GE-Healthcare, Amersham) density gradient centrifugation. Samples were processed within 2 h of collection to avoid any alterations. Regulatory T cells were isolated using a commercial regulatory T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer's instructions. In order to analyze suppressor function, cells were stimulated with anti-CD3 plus anti-CD28 (1 μg/mL) in the presence or absence of previously purified regulatory T cells as previously described \[[@CR16]\]; 1 × 10^5^ of T-CD4^+^CD25^high^ cells (activated regulatory T cells) were co-cultured (or not) with 2 × 10^5^ T-CD4^+^CD25^low^ cells (effector T cells). Purified T-CD4^+^CD25^low^ cells cultured alone were used as controls. After 7 days, cells were pulsed during the last 6 h of culture with 1 μCi \[^3^H\]-thymidine (PerkinElmer, Waltham, MA) and incorporation was measured in glass fiber filters (Filtermat A, Wallac, Oy Turku, Finland) using a 1450 Microbeta luminescence counter (PerkinElmer, Waltham, MA). Regulatory T cell markers were determined by flow cytometry (FACSCalibur). We used anti-CD4 and anti-CD25 (BD Bioscience) and also the anti-FoxP3 staining kit (BD Bioscience) according to the manufacturer's instructions. Cells were stained with anti-CTLA-4, anti-HLA-DR and anti-CD38 in order to measure activation of regulatory T cell markers. Activated T cells were defined as CD4+ CD38+ HLA-DR+ T cells as previously described by the group of Sánchez-Ramón \[[@CR16]\].

### Stimulation and Proliferation Assay {#Sec6}

A total of 10^5^ isolated PBMCs purified from healthy control samples were cultured in medium (GIBCO® RPMI Media 1640---Invitrogen, CA, USA) in the presence of growing concentrations of natalizumab (15, 25, and 125 μg/mL). Cytokine levels were determined in supernatants obtained after 4 and 24 h using flow cytometry. Cells were pulsed with 1 μCi \[^3^H\]-thymidine for 16 h in order to determine proliferation levels.

### Statistical Analysis {#Sec7}

Due to asymmetrical distribution of the serum cytokine levels, summary statistics are given as median and interquartile range. After performing a non-parametric Friedman test in order to analyze significant differences, baseline cytokine levels were compared with levels at each different time-point using the Wilcoxon signed rank test. Patients were grouped depending on their EDSS (0--4, 4.5--6.5) and evidence of relapses (yes or none) during treatment. The same test was also used to compare the levels of regulatory T cell markers as well as the suppressor activity at the different time-points. In order to analyze associations between the number of relapses and the levels of specific cytokines, ranges were calculated for cytokine values by comparing levels (in each patient) at baseline and after 1 year. This allowed comparisons with the number of relapses. Correlations were established by Spearman's test. Also, we tried to correlate result data with the number of observed MRI lesions or the evidence (yes or none) of adverse drug reactions. A simple Mann--Whitney *U* test was used to compare cytokine levels between RRMS patients at baseline with those in healthy donors. *P* \< 0.05 was considered as a significance threshold. Given the exploratory nature of this study, no corrections for multiple comparisons were made. Statistical analyses were performed using GraphPad Prism 5.0 (San Diego, CA, USA).

Results {#Sec8}
=======

Cytokine Levels in Patients After Starting Treatment {#Sec9}
----------------------------------------------------

Globally, patients treated with natalizumab presented higher levels of both pro-inflammatory and anti-inflammatory cytokines on follow-up. Anti-inflammatory interleukins IL-4, IL-5, IL-10, and IL-13 were significantly augmented just a few hours or days after the first administration (Fig. [1](#Fig1){ref-type="fig"}). In counterpart, pro-inflammatory IFN-γ and IL-12p70 were also significantly increased and remained elevated during the first 2 months. Other cytokines included in our study tended to rise (i.e., the IL-6 or IL-17), but no increase reached significance. By the end of the first 2 months, all the cytokines had returned to baseline (non-significant) levels. Fig. 1Serum levels of cytokines in RRMS patients after starting treatment with Natalizumab. Increased levels were detected just few hours or days after first dosing with IFN-γ, IL-12p70 as well as IL-4, IL-5, IL-10, and IL-13, and remained elevated at different stages. By the end of the second month, all the cytokine levels returned to basal levels. Concentrations are given in picograms per milliliter. \**p*\<0.05, \*\**p* \< 0.01, \*\*\**p*\<0.001

Cytokine Levels in Long-Term Treatment {#Sec10}
--------------------------------------

In long-term measurements, levels of specific cytokines were also increased, but the overall response was more dissimilar. Interestingly, while cytokines elevated in the initial stage returned to basal levels, pro-inflammatory IL-17, IL-1β, and IL-2 levels were increased (Fig. [2](#Fig2){ref-type="fig"}). Elevated levels were also obtained for the anti-inflammatory cytokines IL-5 and IL-13 after 1 year of treatment. Fig. 2Long-term effects of natalizumab treatment in cytokine serum levels. Increased concentrations were detected for IL-1β, IL-2, and IL-17 and also for IL-5 and IL-13. Serum levels are shown in picograms per milliliter. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001

Overall, we observed that cytokines were elevated at different time-points and that they followed three different patterns (Fig. [3](#Fig3){ref-type="fig"}). Some of the cytokines (group A) were elevated only during the first month, just a few hours and days after drug infusion. These included both pro-inflammatory and anti-inflammatory cytokines (i.e., IL-4, IL-10, or IFN-γ). In contrast, the typically pro-inflammatory cytokines IL-1β, IL-2, and IL-17 (group B) were elevated only at the long-term treatment. The last group, composed of anti-inflammatory cytokines (IL-5 and IL-13), was elevated at both time-points (group C), the beginning and at 1 year but not at the mid-term. The levels of IL-1α, IL-6, IL-8, TNF-α, GM-CSF, and MCP-1 seemed to be sustained at similar concentrations during treatment and were not significantly elevated at any time-point included in the study (data not shown). Fig. 3Longitudinal pattern of cytokine serum levels after treatment with natalizumab. Three different patterns were observed after initiating treatment with natalizumab in the patient cohort. Some of the cytokines (*Group A*), including IL-4, IL-10, and IFN-γ, were elevated only during the first month. In contrast, another group of pro-inflammatory cytokines (*Group B*, including IL-1β, IL-2 and IL-17) were elevated only at the long-term. The third group (*Group C*), composed of the anti-inflammatory cytokines IL-5 and IL13, was elevated only within the first month and at the end but normal in the mid-term

Regulatory T Cell Frequency and Activity in Patients {#Sec11}
----------------------------------------------------

Overall, the effect of natalizumab treatment on regulatory T cells was not statistically significant. We did not find differences in regulatory T cell frequency, although there was a very slight decrease during the first month (Fig. [4a](#Fig4){ref-type="fig"}). Levels of CD4+ CD25^high^ Foxp3+ cells initially increased but, after 4 days, were back to baseline levels. Looking at the regulatory T cell activity, we also did not observe differences compared to baseline suppressor function of cells previously stimulated with anti-CD3 and anti-CD28 (Fig. [4b](#Fig4){ref-type="fig"}). In addition, there was no difference in CTLA4, CD38, and HLA-DR activation marker levels in the CD4^+^ population. Fig. 4Effects of natalizumab treatment on regulatory T cells. Regulatory T cell frequency (**a**) is shown by following the regulatory T cell markers CD25hi, Foxp3+, and CTLA4. None of the markers changed significantly, although there was a non-significant relative decrease in the first month. HLA-DR and CD38 activation markers were also not affected by treatment (data not shown). In vitro suppressor function of regulatory T cells is also shown (**b**). Peripheral mononuclear cells were stimulated with anti-CD28 plus anti-CD3 in the presence (or not) of purified regulatory T cells in order to obtain percentages of proliferation under different conditions. Proliferation levels of unstimulated cells were considered the control level for suppression (100%)

Natalizumab Effects on PBMCS In Vitro {#Sec12}
-------------------------------------

In vitro exposure to natalizumab does not affect proliferation or cytokine levels. Previous groups addressed this question in CD4+ T cells alone \[[@CR17]\]. However, the VLA-4 antigen is present in many blood cell subtypes, so we co-cultured purified PBMCs in the presence of natalizumab. We did not obtain significantly increased levels of proliferation in cells cultured in the presence of the antibody. Also, we did not obtain significantly different levels of cytokines when natalizumab was present (data not shown) in either 4- or 24-h cultures.

Discussion {#Sec13}
==========

This is the first study to show the effects of natalizumab over a period of 20 months with a special focus on the first hours, days, and months after initiating treatment. At the protein level, we have detected that natalizumab therapy is associated with an increase of pro-inflammatory and anti-inflammatory cytokines within the first 2 months of treatment. This affects IFN-γ and IL-12p70 and also the anti-inflammatory IL-4 or IL-10. Interestingly, important cytokines for MS such as IL-2, IL-17, or IL-1β were only elevated after 1 year of treatment, suggesting different immunologic mechanisms. It would be interesting to further analyze whether the reduction to basal levels in the cytokines after the first 2 months of treatment observed in our study might be associated with the recently described reduction in CD49d antigen expression and therefore a possible reduction of antibody binding in circulating cells \[[@CR18]\]. A recent work has reported increased levels of T cells secreting pro-inflammatory cytokines in blood circulation in patients after 1 year of natalizumab treatment \[[@CR17]\]. In agreement with these results, we observed elevated serum levels of pro-inflammatory IL-2, IL-17, and IL-1β after 1 year.

In our study of cytokines based on serum samples, we have also taken into account the first hours and days after the first administration of the antibody, when we were able to detect differences in cytokine levels such as IFN-γ, IL-4, or IL-10. A recent paper studying cytokines in patients with MS at baseline and after 1 year did not address some of the cytokines included in our study such us IL-17, IL-12p70, or IL-13 \[[@CR19]\]. Our study has detected increased levels for IL-1β, IL-2, and also IL17 in the long-term treatment. It would be interesting to analyze in the future if the IL-23, implicated in Th17 cell induction, would also be increased with natalizumab. Another recent paper has reported increased levels of CD4^+^ T cells producing pro-inflammatory IFN-γ, tumor necrosis factor (TNF), and interleukin (IL)-17 upon stimulation in vitro with anti-CD3 in blood samples from patients after 6 months treatment with natalizumab \[[@CR20]\]. Those authors have also found that the CD4^+^ markers CD25, HLA-DR, and CCR6, as well as the frequency of CD8^+^ T cells producing IL-2 and IL-17, were increased. In agreement with some of these observations, our results also suggest elevated IL-17 levels at the long-term treatment with natalizumab. Although our observations require replication with larger numbers of patients for confirmation, Natalizumab treatment did induce some modifications in cytokine patterns in our cohort of RRMS patients. Furthermore, these responses seemed to be different at several stages; there was a rapid rise in cytokines after the first administration when rejection and allergic reaction might occur, whereas other cytokines were only elevated at the long-term treatment when the risk of opportunistic infections or PML risk is higher.

Natalizumab was not designed to have biological effects upon binding to α4 but rather to physically interfere with the endothelial attachment of VLA-4^+^ cells \[[@CR1]\]. However, previous studies in rats suggested that antibody binding to VLA-4 might mediate VLA-4^+^ cell stimulation \[[@CR21], [@CR22]\]. As we observed different cytokine response patterns in patients, we decided to test whether natalizumab exposure might affect mononuclear cells in vitro. Previous groups have addressed this question for CD4+ T cells \[[@CR17]\]. Since the VLA-4 antigen is present in many blood cell subtypes, we co-cultured total purified PBMCs in the presence of physiological concentrations of natalizumab. We did not detect significant effects on proliferation, and we did not observe differences in cytokine patterns when the antibody was present. Therefore, if natalizumab does have any effect on blood cells, these effects might be more than just on proliferation or cytokine production and should be further addressed. It would be important to mention that this effect (if it exists) might depend on the subject or patient studied (note that we only used healthy donors because of the heterogeneity of RRMS patients).

In accordance with recent studies, we found that natalizumab does not affect regulatory T cell function. A recent study showed that the capacity to migrate across the blood brain barrier and suppressive function as well as foxp3+ cell frequency seem to not be affected by natalizumab \[[@CR18]\]. At this time, there are contradictory results on the effect of natalizumab on the frequency of circulating regulatory T cells and another group has reported a relative decrease in CD4+ CD25^high^ cells \[[@CR23]\]. However, none of these studies have found any effect on the suppressor function of the cells \[[@CR18], [@CR23]\]. In our case, we detected a relative tendency to a decrease in the frequency of CD4+ CD25 FoxP3+ cells within the first month (not significant); however, we also did not obtain any difference in the suppressor function of these cells in comparison with baseline levels. It would also be interesting to consider other regulatory T cell markers in our study like the ILR-7 receptor (CD127) or the CD39 ectonucleotidase \[[@CR24]\], but, unfortunately, this was not considered at the beginning of our study. Already existing drugs for MS like interferon-beta and glatiramer acetate seem to modify CD4^+^ CD25 ^+^ Foxp3 regulatory T cell activity \[[@CR7]--[@CR10]\]. Regulatory T cells have been described as important players in controlling immune response and balancing tolerance versus autoimmune responses \[[@CR25], [@CR26]\]. Our results, in accordance with some of the previous reports suggest that natalizumab seems to exert its beneficial properties independently of affecting regulatory T cell function.

In summary, treatment with natalizumab in RRMS patients induces changes in the inflammatory mechanism. While IFN-γ, IL-12p70, IL-4, and IL-10 were elevated just a few hours or days after first IV infusion, pro-inflammatory cytokines like IL-1β, IL-2, and IL-17 were elevated only at the long-term treatment suggesting different immune mechanisms. We have found that globally the treatment with the antibody does not modify regulatory T cell function. All these results suggest other immunological effects of natalizumab in addition to VLA-4 interaction and CNS extravasation inhibition. If these changes in the cytokine equilibrium are related to beneficial or negative side effects associated to natalizumab is as yet unknown and requires further investigation.
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